Role of Long Noncoding RNAs in Neoplasia: Special Emphasis on Prostate Cancer

Alahari, SK; Eastlack, Steven; Alahari, Suresh K.

doi:10.1016/bs.ircmb.2016.01.004

Cited by 25 publications

(25 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12, 27, 28, 29 Previous studies indicated that BLACAT1 is overexpressed in bladder cancer, gastric cancer 22, 23 and acted as the negative prognostic factor. However, the expression and roles of BLACAT1 in CRC are not being elucidated.…”

Section: Discussionmentioning

confidence: 99%

Long noncoding RNA BLACAT1 indicates a poor prognosis of colorectal cancer and affects cell proliferation by epigenetically silencing of p15

et al. 2017

View full text Add to dashboard Cite

Recently, a novel class of transcripts, long noncoding RNAs (lncRNAs), is being identified at a rapid pace. These RNAs have critical roles in diverse biological processes, including tumorigenesis. One of them, BLACAT1, a cancer-associated long noncoding RNA, exerts regulatory functions in various biological processes in cancer cells, however, the role of BLACAT1 in colon cancer remains unclear. Our experiments showed that increased BLACAT1 was an independent unfavorable prognostic indicator for colorectal cancer, and revealed that BLACAT1 knockdown significantly repressed proliferation, both in vitro and in vivo. Mechanistic investigations demonstrated that BLACAT1 had a key role in G1/G0 arrest, and showed that BLACAT1 can repress p15 expression by binding to EZH2, thus contributing to the regulation of CRC cell cycle and proliferation. Our results suggest that BLACAT1, as a cell cycle regulator, may serve as a potential target for colon cancer prevention and treatment in human CRC.

show abstract

Section: Discussionmentioning

confidence: 99%

Long noncoding RNA BLACAT1 indicates a poor prognosis of colorectal cancer and affects cell proliferation by epigenetically silencing of p15

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In another hand, the research field of noncoding RNA (ncRNA) should be paid more attention. The ncRNAs consist of tRNA, rRNA, snoRNA, snRNA, piRNA, miRNA, and lncRNA [59]. Of them, miRNA and lncRNA are familiar and studied more.…”

Section: Transcriptomicsmentioning

confidence: 99%

Recognition of Multiomics-Based Molecule-Pattern Biomarker for Precise Prediction, Diagnosis, and Prognostic Assessment in Cancer

Zhan¹,

Zhou²,

Cheng³

et al. 2019

Bioinformatics Tools for Detection and Clinical Interpretation of Genomic Variations

View full text Add to dashboard Cite

Cancer is a complex whole-body chronic disease, is involved in multiple causes, multiple processes, and multiple consequences, which are associated with a series of molecular alterations in the different levels of genome, transcriptome, proteome, metabolome, and radiome, with between-molecule mutual interactions. Those molecule-panels are the important resources to recognize the reliable molecular pattern biomarkers for precise prediction, diagnosis, and prognostic assessment in cancer. Pattern recognition is an effective methodology to identify those moleculepanels. The rapid development of computation biology, systems biology, and multiomics is driving the development of pattern recognition to discover reliable molecular pattern biomarkers for cancer treatment. This book chapter addresses the concept of pattern recognition and pattern biomarkers, status of multiomics-based molecular patterns, and future perspective in prediction, diagnosis, and prognostic assessment of a cancer.

show abstract

“…For instance, in just two weeks of Medline updates we found papers on long non-coding RNAs 52 , ALKBH3 53 , two different approaches to MicroRNAs 54,55 , a surface-enhanced Raman scattering (SERS)-based microdroplet sensor for PSA 56 , urinary carbonic anhydrase IX splicing messenger RNA 57 , prostate specific membrane antigen (PSMA) 58 , and platelet factor-4 (PF-4) 58 . Here we review some of the most prominent recent markers.…”

Section: Other Markersmentioning

confidence: 99%

Beyond prostate-specific antigen

Loeb

Lilja

2016

Current Opinion in Urology

View full text Add to dashboard Cite

Purpose of Review The purpose of this article is to review blood and urine tests that are currently available and under investigation for a role in prostate cancer screening and detection. Recent Findings Compared to total PSA alone, its combination with percent free-to-total PSA contributes greater specificity for prostate cancer, and is a component of 2 newer blood tests called the 4kScore and Prostate Health Index. All three tests improve the prediction of high-grade disease and are commercially available options to aid in initial or repeat prostate biopsy decisions. PCA3 is a urinary marker that is currently available for repeat prostate biopsy decisions. Although PCA3 alone has inferior prediction of clinically significant disease and requires collection of urine after digital rectal examination, it may be combined with other clinical variables or other urine markers like TMPRSS2:ERG to improve performance. Little data is available to support a role for single nucleotide polymorphisms or other investigational markers in early detection. Summary Several commercially available blood and urine tests have to been shown to improve specificity of PSA for high-grade prostate cancer. Use of such tests would decrease unnecessary biopsy and overdiagnosis of indolent disease. Biopsy of men with moderately elevated PSA without use of such a reflex test should be discouraged.

show abstract

Role of Long Noncoding RNAs in Neoplasia: Special Emphasis on Prostate Cancer

Cited by 25 publications

References 108 publications

Long noncoding RNA BLACAT1 indicates a poor prognosis of colorectal cancer and affects cell proliferation by epigenetically silencing of p15

Long noncoding RNA BLACAT1 indicates a poor prognosis of colorectal cancer and affects cell proliferation by epigenetically silencing of p15

Recognition of Multiomics-Based Molecule-Pattern Biomarker for Precise Prediction, Diagnosis, and Prognostic Assessment in Cancer

Beyond prostate-specific antigen

Contact Info

Product

Resources

About